- Home
- IDYA vs QDEL Comparison
IDYA vs QDEL Comparison
Compare IDYA & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- QDEL
- Stock Information
- Founded
- IDYA 2015
- QDEL 1979
- Country
- IDYA United States
- QDEL United States
- Employees
- IDYA N/A
- QDEL N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- QDEL Medical Specialities
- Sector
- IDYA Health Care
- QDEL Health Care
- Exchange
- IDYA Nasdaq
- QDEL Nasdaq
- Market Cap
- IDYA 2.3B
- QDEL 2.1B
- IPO Year
- IDYA 2019
- QDEL N/A
- Fundamental
- Price
- IDYA $32.18
- QDEL $27.94
- Analyst Decision
- IDYA Buy
- QDEL Hold
- Analyst Count
- IDYA 17
- QDEL 6
- Target Price
- IDYA $48.20
- QDEL $39.00
- AVG Volume (30 Days)
- IDYA 1.3M
- QDEL 1.2M
- Earning Date
- IDYA 11-04-2025
- QDEL 11-05-2025
- Dividend Yield
- IDYA N/A
- QDEL N/A
- EPS Growth
- IDYA N/A
- QDEL N/A
- EPS
- IDYA N/A
- QDEL N/A
- Revenue
- IDYA $7,000,000.00
- QDEL $2,741,600,000.00
- Revenue This Year
- IDYA $90.17
- QDEL N/A
- Revenue Next Year
- IDYA $219.42
- QDEL $2.65
- P/E Ratio
- IDYA N/A
- QDEL N/A
- Revenue Growth
- IDYA N/A
- QDEL N/A
- 52 Week Low
- IDYA $13.45
- QDEL $22.05
- 52 Week High
- IDYA $33.64
- QDEL $49.45
- Technical
- Relative Strength Index (RSI)
- IDYA 67.18
- QDEL 46.78
- Support Level
- IDYA $28.17
- QDEL $25.48
- Resistance Level
- IDYA $33.64
- QDEL $30.85
- Average True Range (ATR)
- IDYA 1.68
- QDEL 1.25
- MACD
- IDYA 0.40
- QDEL -0.02
- Stochastic Oscillator
- IDYA 80.76
- QDEL 45.81
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.